
India · Medical devices startup
Serigen Mediproducts Private Limited is a tissue regeneration company based in Pune, Maharashtra, founded in 2015.
Funding reportedLast round: Seed
Follow Serigen Mediproducts (Official account) and see its new rounds in your feed.Start following
Serigen Mediproducts Private Limited is a tissue regeneration company based in Pune, Maharashtra, founded in 2015.
The company specializes in developing biomedical devices using natural silk proteins to address challenges in bone, soft tissue, and skin repair. Founded by Dr. Anuya Nisal and her co-founders after extensive research at the CSIR-National Chemical Laboratory, Serigen leverages India's sericulture ecosystem to create affordable and effective regenerative medicine products. Serigen's primary focus is on next-generation tissue engineering solutions that utilize silk protein biomaterials. Their flagship products include Serioss, an osteoconductive bone void filler; Seriderm, an absorbent wound dressing; and Serimat, a silk protein mesh for soft tissue reconstruction. The company operates on a B2B model, targeting clinicians and hospitals in need of high-performance alternatives to synthetic grafts. With plans for global expansion, Serigen aims to lead the market in silk-based regenerative medicine.
Funding, as reported
From Serigen Mediproducts (Official account)'s own website: 3 founders.
What they build
Known for
health careconsumersadvanced wound carebiocompatible scaffoldsmedical implantsimpact in orthopedicssilk-based biomaterialsmedical equipment manufacturingbiomaterial sciencepatent protectedinformation technology & serviceshospital & health carenonhealing trauma woundsbiomaterial processinghealthbiotechnology
Built with from their website
Contact Form 7Google Tag ManagerAmazon CloudFrontEpsilon DataGoogle SheetsCaptifyWordPress.orgHostinger CDNAtlassianFreeWheel
LiveRampGoogle CloudExit BeeFlashtalkingRealyticsFont AwesomeTarget PerformanceElementor
Add your raise, your deck and your story, and put Serigen Mediproducts (Official account) in front of investors. Or tell us what we have wrong.